Deutschland
India
Lietuva
United Kingdom
Search
Search
Search
Looking toward the future of kinases in immunology, the path forward is anything but clear cut. As more next-gen JAK and JAK-adjacent therapies progress toward entering the market, there are a number of challenges that will be key factors in determining the success of these agents.
The potentially bifurcated way in which health authorities in the US and EU may handle JAK safety concerns will have downstream implications in each market. Regulators’ differing approaches will impact line of therapy and require developers to tailor commercial strategies on a per-geography basis to account for differing competitive landscapes and subsequent clinical trial comparators as well as pricing and access strategy.
Guidehouse is a global advisory, technology, and managed services firm delivering value to commercial businesses and federal, state, and local governments. Serving industries focused on communities, energy, infrastructure, healthcare, financial services, defense, and national security, Guidehouse positions clients for AI-led innovation, efficiency, and resilience.